- Home
- ASPC vs ADAG Comparison
ASPC vs ADAG Comparison
Compare ASPC & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPC
- ADAG
- Stock Information
- Founded
- ASPC 2024
- ADAG 2011
- Country
- ASPC Hong Kong
- ADAG China
- Employees
- ASPC N/A
- ADAG N/A
- Industry
- ASPC
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- ASPC
- ADAG Health Care
- Exchange
- ASPC Nasdaq
- ADAG Nasdaq
- Market Cap
- ASPC 82.3M
- ADAG 76.3M
- IPO Year
- ASPC 2024
- ADAG 2021
- Fundamental
- Price
- ASPC $10.22
- ADAG $1.90
- Analyst Decision
- ASPC
- ADAG Strong Buy
- Analyst Count
- ASPC 0
- ADAG 1
- Target Price
- ASPC N/A
- ADAG $8.00
- AVG Volume (30 Days)
- ASPC 9.6K
- ADAG 75.4K
- Earning Date
- ASPC 01-01-0001
- ADAG 07-24-2025
- Dividend Yield
- ASPC N/A
- ADAG N/A
- EPS Growth
- ASPC N/A
- ADAG N/A
- EPS
- ASPC 0.05
- ADAG N/A
- Revenue
- ASPC N/A
- ADAG $103,204.00
- Revenue This Year
- ASPC N/A
- ADAG $6,488.89
- Revenue Next Year
- ASPC N/A
- ADAG $57.50
- P/E Ratio
- ASPC $219.99
- ADAG N/A
- Revenue Growth
- ASPC N/A
- ADAG N/A
- 52 Week Low
- ASPC $9.95
- ADAG $1.33
- 52 Week High
- ASPC $10.70
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- ASPC N/A
- ADAG 52.47
- Support Level
- ASPC N/A
- ADAG $1.73
- Resistance Level
- ASPC N/A
- ADAG $2.02
- Average True Range (ATR)
- ASPC 0.00
- ADAG 0.15
- MACD
- ASPC 0.00
- ADAG -0.01
- Stochastic Oscillator
- ASPC 0.00
- ADAG 42.50
About ASPC A SPAC III Acquisition Corp. Class A Ordinary Shares
A SPAC III Acquisition Corp is a blank check company.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.